Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Campaign Launched to Raise Awareness of Risks of Familial Hypercholesterolaemia (FH)


News provided by

Sanofi UK

13 Jul, 2015, 09:58 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
Heart of the Family logo (PRNewsFoto/Sanofi UK) (PRNewsFoto/Sanofi UK)

GUILDFORD, England, July 13, 2015 /PRNewswire/ --

New survey shows two out of five GPs unde restimate the prevalence of FH 

Sanofi UK, with the endorsement of HEART UK-The Cholesterol Charity, has today launched a new campaign to help break family cycles of early heart disease and death from Familial Hypercholesterolaemia (FH). Heart of the Family aims to increase awareness of FH to encourage earlier diagnosis and testing of family members as prompt diagnosis and appropriate treatment can help save lives.[1]

     (Logo: http://photos.prnewswire.com/prnh/20150713/235439LOGO )

FH is a treatable, genetic condition characterised by abnormally high cholesterol levels from birth, which affects approximately 1 in 500 people in the UK; about the same number of children and young people under 19 years old are affected by type 1 diabetes.[2],[3] However, 85% of people with FH remain undiagnosed and untreated, putting them at increased risk of premature heart disease and death.[2],[4] A new online survey of 150 UK GPs, commissioned by Sanofi, shows that two out of five (39%) under-estimated the prevalence of FH and a further third (33%) recognise that there is a need for increased awareness among GPs.[5]

"FH is a silent assassin and too often goes undetected until it's too late," said Dr Sarah Jarvis, GP and past chair of the Healthcare Committee at HEART UK. "The Heart of the Family campaign aims to drive earlier diagnosis, testing and appropriate treatment to ultimately save lives from preventable heart disease."

Jules Payne, Chief Executive of HEART UK - the Cholesterol Charity said: "FH is an inherited condition which leads to exceptionally high cholesterol levels, often double or three times those of the general population. It is not caused by an unhealthy lifestyle, but is passed from generation to generation through a "faulty" gene. Early diagnosis and effective treatment reduces the risk of heart disease and can help ensure that people with FH have a normal life expectancy."

According to the GP survey, although approximately two thirds of GPs (68%) said they feel somewhat confident about identifying FH, many were unclear about who to refer for testing and when.[5] Only just over half (53%) would refer patients and their first generation relatives for confirmation of diagnosis and DNA testing.[5] This dropped to less than one in ten (7%) for second generation relatives and just 1% would refer third generation relatives.[5] In addition, only one in five GPs surveyed (20%) correctly identified that children who may have FH should be tested before age 10.[5]

The clinical indicators of FH include abnormally high cholesterol levels, a family history of high cholesterol or early heart disease and in some cases fatty deposits that can appear under the eyes or in the eyelids.[6] Most people with FH have inherited a defective gene from at least one parent and therefore will have had high cholesterol levels from birth.[1]

Dr Sarah Jarvis explains: "FH is not caused by an unhealthy lifestyle, but is passed from generation to generation through a faulty or altered gene. Siblings and children of someone with FH have a 50% risk of inheriting it themselves, but it can also affect second and third generation relatives, so it is therefore vital that family members are tested for FH as early as possible."

If left untreated, approximately 50% of men and 30% of women with FH will have developed heart disease by the time they are 50 and 60 years old respectively due to a life-long exposure to high cholesterol.[2] Following a diagnosis of FH, treatment includes prescription of cholesterol-lowering medications along with dietary and lifestyle advice.[2],[4]

"Preventing premature heart disease and death, which can devastate families across generations, is possible if FH is diagnosed and treated early," said Dr David Williams, Medical Director, Sanofi. "That's why we want to encourage people to be aware of FH and ensure they know their cholesterol levels."

How to get involved: 

  • Share our videos - visit http://www.heartofthefamily.co.uk to hear family stories about living with FH and commentary from Dr Sarah Jarvis. This website is developed and funded by Sanofi  
  • If you or your family have a history of high cholesterol, heart disease or early heart attacks or strokes, visit your doctor to get your cholesterol tested

Notes to Editors 

About Heart of the Family 

The Heart of the Family Campaign aims to increase awareness of, and testing for, hereditary high cholesterol; a disease known as Familial Hypercholesterolaemia or FH. It will do this through:

  • Sharing family stories of living with FH - these can be viewed at http://www.heartofthefamily.co.uk
  • Encouraging earlier presentation, diagnosis and referral for testing of appropriate family members

The Heart of the Family Campaign is developed and funded by Sanofi UK, with the endorsement of HEART UK - The Cholesterol Charity.

About Sanofi 

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About HEART UK - The Cholesterol Charity 

Providing support, guidance and education services to healthcare professionals and people and families with concerns about cholesterol - see more at: http://www.heartuk.org.uk

References 

  1. Heart UK. Familial Hypercholesterolaemia. Available at: http://heartuk.org.uk/fh-familial-hypercholesterolemia [Last accessed 22 April 2015].
  2. NICE, Identification and management of familial hypercholesterolaemia. Clinical Guidelines 71. 2008. guidance.nice.org.uk/cg71 [Last accessed April 2015].
  3. Diabetes UK : facts and stats. Care Connect Campaign, Version 3, revised March 2014. Available at : https://www.diabetes.org.uk/Documents/About%20Us/Statistics/Diabetes-key-stats-guidelines-April2014.pdf (last accessed June, 2015)
  4. Heart UK. Familial Hypercholesterolaemia. Treatment for Familial Hypercholesterolaemia: FH Facts and Figures. Available at: http://heartuk.org.uk/fh-familial-hypercholesterolemia/treatment-for-familial-hypercholesterolaemia-fh [Last accessed April, 2015].
  5. Sanofi data on file, May 2015, reference number: SAGB.CMR.15.05.0643
  6. The British Heart Foundation in association with Heart UK, 2014. Life with Familial Hypercholesterolaemia. Available at: http://heartuk.org.uk/files/uploads/FINAL_COPY2014_Life_with_Familial_Hypercholesterolaemia.pdf [Last accessed 22 April, 2015].

Contacts:

Sanofi
Olivia Bailey / Tessa Duggleby
Tel: +44-(0)1483-554212
Email: Olivia.Bailey@sanofi.com / Tessa.Duggleby@sanofi.com

Red Door Unlimited
Abigail Thomson / Lucy Thornton Jones
Tel: +44-(0)20-8392-8049 / +44-(0)20-8392-6091
Email: athomson@reddoorunlimited.com / lthorntonjones@reddoorunlimited.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.